Browse > Article
http://dx.doi.org/10.15433/ksmb.2021.13.2.086

Facilitation of cisplatin-induced acute kidney injury by high salt intake through increased inflammatory response  

Ji, Seon Yeong (Anti-Aging Research Center, Dong-eui University)
Hwangbo, Hyun (Anti-Aging Research Center, Dong-eui University)
Kim, Min Yeong (Anti-Aging Research Center, Dong-eui University)
Kim, Da Hye (Anti-Aging Research Center, Dong-eui University)
Park, Beom Su (Department of Biochemistry, College of Korean Medicine, Dong-eui University)
Park, Joung-Hyun (Ocean Fisheries & Biology Center, Marine Bioprocess Co., Ltd.)
Lee, Bae-Jin (Ocean Fisheries & Biology Center, Marine Bioprocess Co., Ltd.)
Lee, Hyesook (Anti-Aging Research Center, Dong-eui University)
Choi, Yung Hyun (Department of Biochemistry, College of Korean Medicine, Dong-eui University)
Publication Information
Journal of Marine Bioscience and Biotechnology / v.13, no.2, 2021 , pp. 86-93 More about this Journal
Abstract
A high salt diet contributes to kidney damage by causing hypoxia and oxidative stress. Recently, an increase in dietary salt has been reported to induce an inflammatory phenotype in immune cells, further contributing to kidney damage. However, studies on the exact mechanism and role of a high salt diet on the inflammatory response in the kidneys are still insufficient. In this study, a cisplatin-induced acute kidney injury model using C57BL/6 mice was used to analyze the effect of salt intake on kidney injury. Results showed that high salt administration aggravated kidney edema in mice induced by treatment with cisplatin. Moreover, the indicators of kidney and liver function impairment were significantly increased in the group cotreated with high salt compared with that treated with cisplatin alone. Furthermore, the exacerbation of kidney damage by high salt administration was also associated with a decrease in the number of cells in the immune regulatory system. Additionally, high salt administration further decreased renal perfusion functions along with increased cisplatin-induced damage to proximal tubules. This was accompanied by increased expression of T cell immunoglobulin, mucin domain 1 (a biomarker of kidney injury), and Bax (a pro-apoptotic factor). Moreover, cisplatin-induced expression of proinflammatory mediators and cytokines, including cyclooxygenase-2 and tumor necrosis factor-α in kidney tissue, was further increased by high salt intake. Therefore, these results indicate that the kidney's inflammatory response by high salt treatment can further promote kidney damage caused by various pathological factors.
Keywords
High-salt; kidney injury; cisplatin; renal perfusion; inflammation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Chen, Q., Guan, X., Zuo, X., Wang, J., Yin, W. 2016. The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases. Acta. Pharm. Sin. B. 6, 183-188.   DOI
2 Karmakova, T. A., Sergeeva, N. S., Kanukoev, K. Y., Alekseev, B. Y., Kaprin, A. D. 2021. Kidney injury molecule 1 (KIM-1): a multifunctional glycoprotein and biological marker (Review). Sovrem. Tekhnologii. Med. 13, 64-78.
3 Bovee, D. M., Cuevas, C. A., Zietse, R., Danser, A. H. J., Mirabito Colafella, K. M., Hoorn, E. J. 2020. Salt-sensitive hypertension in chronic kidney disease: Distal tubular mechanisms. Am. J. Physiol. Renal Physiol. 319, F729-F745   DOI
4 Majid, D. S., Prieto, M. C., Navar, L. G. 2015. Salt-sensitive hypertension: perspectives on intrarenal mechanisms. Curr. Hypertens. Rev. 11, 38-48.   DOI
5 Ren, J., Crowley, S. D. 2019. Role of T-cell activation in salt-sensitive hypertension. Am. J. Physiol. Heart Circ. Physiol. 316, H1345-H1353.   DOI
6 Mattson, D. L. 2014. Infiltrating immune cells in the kidney in salt-sensitive hypertension and renal injury. Am. J. Physiol. Renal Physiol. 307, F499-508.   DOI
7 Hirohama, D., Fujita, T. 2019. Evaluation of the pathophysiological mechanisms of salt-sensitive hypertension. Hypertens. Res. 42, 1848-1857.   DOI
8 Griffin, B. R., Faubel, S., Edelstein, C. L. 2019. Biomarkers of drug-induced kidney toxicity. Ther. Drug Monit. 41, 213-226.   DOI
9 Saritas, T., Kramann, R. 2021. Kidney allograft fibrosis: Diagnostic and therapeutic strategies. Transplantation 105, e114-e130.   DOI
10 Liu, F., Zhuang, S. 2019. New therapies for the treatment of renal fibrosis. Adv. Exp. Med. Biol. 1165, 625-659.   DOI
11 Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P., Kumar, S. 2021. Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy. J. Exp. Pharmacol. 13, 303-328.   DOI
12 Dasari, S., Tchounwou, P. B. 2014. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 740, 364-378.   DOI
13 Gentilin, E., Simoni, E., Candito, M., Cazzador, D., Astolfi, L. 2019. Cisplatin-induced ototoxicity: Updates on molecular targets. Trends Mol. Med. 25, 1123-1132.   DOI
14 Perse, M., Veceric-Haler, Z. 2018. Cisplatin-induced rodent model of kidney injury: Characteristics and challenges. Biomed. Res. Int. 2018, 1462802.
15 Sankhe, R., Kinra, M., Mudgal, J., Arora, D., Nampoothiri, M. 2020 Neprilysin, the kidney brush border neutral proteinase: a possible potential target for ischemic renal injury. Toxicol. Mech. Methods 30, 88-99.   DOI
16 Belavgeni, A., Meyer, C., Stumpf, J., Hugo, C., Linkermann, A. 2020. Ferroptosis and necroptosis in the kidney. Cell. Chem. Biol. 27, 448-462.   DOI
17 Yang, R., Zhu, S., Tonnessen, T. I. 2016. Ethyl pyruvate is a novel anti-inflammatory agent to treat multiple inflammatory organ injuries. J. Inflamm. (Lond) 3, 13:37.   DOI
18 Mehaffey, E., Majid, D. S. A. 2017. Tumor necrosis factor-alpha, kidney function, and hypertension. Am. J. Physiol. Renal Physiol. 313, F1005-F1008.   DOI
19 Lu, X., Crowley, S. D. 2018. Inflammation in salt-sensitive hypertension and renal damage. Curr. Hypertens. Rep. 20, 103.   DOI
20 Abdelrahman, A. M., Al Suleimani, Y., Shalaby, A., Ashique, M., Manoj, P., Al-Saadi, H., Ali, B.H. 2019. Effect of levosimendan, a calcium sensitizer, on cisplatin-induced nephrotoxicity in rats. Toxicol. Rep. 6, 232-238.   DOI
21 Molina, P., Gavela, E., Vizcaino, B., Huarte, E., Carrero, J. J. 2021. Optimizing diet to slow CKD progression. Front. Med. (Lausanne) 8, 654250.
22 Brown, A., Kumar, S., Tchounwou, P. B. 2019. Cisplatin-based chemotherapy of human cancers. J. Cancer Sci. Ther. 11, 97.
23 Achkar, I. W., Abdulrahman, N., Al-Sulaiti, H., Joseph, J. M., Uddin, S., Mraiche, F. 2018. Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway. J. Transl. Med. 16, 96.   DOI
24 Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., Perkovic, V. 2021. Chronic kidney disease. Lancet 398, 786-802.   DOI
25 McSweeney, K. R., Gadanec, L. K., Qaradakhi, T., Ali, B. A., Zulli A., Apostolopoulos, V. 2021, Mechanisms of cisplatin-induced acute kidney injury: Pathological mechanisms, pharmacological interventions, and genetic mitigations. Cancers (Basel) 13, 1572.   DOI
26 Xiang, X., Guo, C., Tang, C., Cai, J., Dong, Z. 2019. Epigenetic regulation in kidney toxicity: Insights from cisplatin nephrotoxicity. Semin. Nephrol. 39, 152-158.   DOI
27 Holditch, S. J., Brown, C. N., Lombardi, A. M., Nguyen, K. N., Edelstein, C. L. 2019. Recent advances in models, mechanisms, biomarkers, and interventions in cisplatin-induced acute kidney injury. Int. J. Mol. Sci. 20, 3011.   DOI
28 Taghizadeh, F., Hosseinimehr, S. J., Zargari, M., Karimpour Malekshah, A., Talebpour Amiri, F. B. 2020. Gliclazide attenuates cisplatin-induced nephrotoxicity through inhibiting NF-kappaB and caspase-3 activity. IUBMB Life 72, 2024-2033.   DOI
29 Wen, Y., Yan, H. R., Wang, B., Liu, B. C. 2021.,Macrophage heterogeneity in kidney injury and fibrosis. Front. Immunol. 12, 681748.   DOI
30 Lin, S., Lin, W., Liao, C., Zhou, T. 2020. Nephroprotective effect of mesenchymal stem cell-based therapy of kidney disease induced by toxicants. Stem Cells Int. 2020, 8819757.
31 Frazier, K. S., Ryan, A. M., Peterson, R. A., Obert, L. A. 2019. Kidney pathology and investigative nephrotoxicology strategies across species. Semin. Nephrol. 39, 190-201.   DOI
32 Dong, Q., Jie, Y., Ma, J., Li, C., Xin, T., Yang, D. 2019. Renal tubular cell death and inflammation response are regulated by the MAPK-ERK-CREB signaling pathway under hypoxia-reoxygenation injury. J Recept. Signal. Transduct. Res. 39, 383-391.   DOI
33 Zhao, Z., Hu, Z., Zeng, R., Yao, Y. 2020. HMGB1 in kidney diseases. Life Sci. 15, 259:118203.   DOI
34 Brooks, C. R., Bonventre, J. V. 2015. KIM-1/TIM-1 in proximal tubular cell immune response. Oncotarget 6, 44059-44060.   DOI
35 Zhao, X. C., Livingston, M. J., Liang, X. L., Dong, Z. 2019. Cell apoptosis and autophagy in renal fibrosis. Adv. Exp. Med. Biol. 1165, 557-584.   DOI
36 Soetikno, V., Sari, S. D. P., Ul Maknun, L., Sumbung, N. K., Rahmi, D. N. I., Pandhita, B. A. W., Louisa, M., Estuningtyas, A. 2019. Pre-treatment with curcumin ameliorates cisplatin-induced kidney damage by suppressing kidney inflammation and apoptosis in rats. Drug Res. (Stuttg) 69, 75-82.   DOI
37 Basu, S. 2007. Novel cyclooxygenase-catalyzed bioactive prostaglandin F2 alpha from physiology to new principles in inflammation. Med. Res. Rev. 27, 435-468.   DOI
38 Potocnjak, I., Domitrovic, R. 2016. Carvacrol attenuates acute kidney injury induced by cisplatin through suppression of ERK and PI3K/Akt activation. Food Chem. Toxicol. 98, 251-261.   DOI
39 Hajian, S., Rafieian-Kopaei, M., Nasri, H. 2014. Renoprotective effects of antioxidants against cisplatin nephrotoxicity. J. Nephropharmacol. 3, 39-42.